Forte Biosciences, Inc. (FBRX)
76.99
0.00 (0.00%)
USD |
NASDAQ |
Oct 13, 16:00
Forte Biosciences Free Cash Flow : -72.03M for June 30, 2026
Free Cash Flow Chart
Historical Free Cash Flow Data
| Date | Value |
|---|---|
| June 30, 2026 | -72.03M |
| March 31, 2026 | -59.39M |
| December 31, 2025 | -51.00M |
| September 30, 2025 | -44.57M |
| June 30, 2025 | -38.65M |
| March 31, 2025 | -34.52M |
| December 31, 2024 | -30.78M |
| September 30, 2024 | -29.73M |
| June 30, 2024 | -30.72M |
| March 31, 2024 | -30.26M |
| December 31, 2023 | -28.79M |
| September 30, 2023 | -22.70M |
| June 30, 2023 | -15.51M |
| March 31, 2023 | -11.41M |
| December 31, 2022 | -8.185M |
| September 30, 2022 | -8.874M |
| June 30, 2022 | -12.06M |
| March 31, 2022 | -14.62M |
| Date | Value |
|---|---|
| December 31, 2021 | -16.68M |
| September 30, 2021 | -16.90M |
| June 30, 2021 | -19.51M |
| March 31, 2021 | -19.59M |
| December 31, 2020 | -18.42M |
| September 30, 2020 | -15.36M |
| June 30, 2020 | -8.249M |
| March 31, 2020 | 12.02M |
| December 31, 2019 | -2.933M |
| September 30, 2019 | -14.61M |
| June 30, 2019 | -13.65M |
| March 31, 2019 | -41.32M |
| December 31, 2018 | -36.44M |
| September 30, 2018 | -33.51M |
| June 30, 2018 | -41.11M |
| March 31, 2018 | -37.10M |
| December 31, 2017 | -31.79M |
Free Cash Flow Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Free Cash Flow Benchmarks
| argenx SE | 1.090B |
| ACADIA Pharmaceuticals, Inc. | 145.62M |
| Alnylam Pharmaceuticals, Inc. | 793.94M |
| Anika Therapeutics, Inc. | 0.562M |
| Savara, Inc. | -110.66M |
Free Cash Flow Related Metrics
| Cash from Operations (Quarterly) | -22.70M |
| Cash from Investing (Quarterly) | -147.84M |
| Cash from Financing (Quarterly) | 161.95M |
| Free Cash Flow Per Share (Quarterly) | -0.9544 |
| Free Cash Flow to Equity (Quarterly) | -22.70M |
| Free Cash Flow to Firm (Quarterly) | -22.70M |
| Free Cash Flow Yield | -5.17% |